{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:51Z","timestamp":1793144271108,"version":"4.5.0"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,12,1]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antisynthetase syndrome (ASyS) is a rare autoimmune connective tissue disease (CTD), associated with autoantibodies targeting tRNA synthetase enzymes, that can present to respiratory (interstitial lung disease (ILD)) or rheumatology (myositis, inflammatory arthritis and systemic features) services. The therapeutic management of CTD-associated ILD and idiopathic pulmonary fibrosis (IPF) differs widely, thus accurate diagnosis is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a retrospective, multicentre observational cohort study designed to (1) evaluate differences between ASyS-associated ILD with IPF, (2) phenotypic differences in patients with ASyS-ILD presenting to respiratory versus rheumatology services, (3) differences in outcomes between ASySassociated with Jo-1 versus non-Jo-1 autoantibodies and (4) compare long-term outcomes between these groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 76 patients with ASyS-ILD and 78 with IPF. Patients with ASyS were younger at presentation (57 vs 77 years, p&lt;0.001) with a female predominance (57% vs 33%, p=0.006) compared with IPF. Cytoplasmic staining on indirect immunofluorescence was a differentiating factor between ASyS and IPF (71% vs 0%, p&lt;0.0001). Patients with ASyS presenting initially to respiratory services (n=52) had a higher prevalence of ASyS non-Jo-1 antibodies and significantly fewer musculoskeletal symptoms\/biochemical evidence of myositis, compared with those presenting to rheumatology services (p&lt;0.05), although lung physiology was similar in both groups. There were no differences in high-resolution CT appearances or outcomes in those with Jo-1 versus non-Jo-1 ASyS-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Extended autoimmune serology is needed to evaluate for ASyS autoantibodies in patients presenting with ILD, particularly in younger female patients. Musculoskeletal involvement is common in ASyS (typically Jo-1 autoantibodies) presenting to rheumatology but the burden of ILD is similar to those presenting to respiratory medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2020-000829","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T12:38:22Z","timestamp":1610109502000},"page":"e000829","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7349","authenticated-orcid":false,"given":"Shaney L","family":"Barratt","sequence":"first","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"},{"name":"School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havra H","family":"Adamali","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cotton","sequence":"additional","affiliation":[{"name":"Liverpool Interstitial Lung Disease Service, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Mulhearn","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, Somerset, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Iftikhar","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John David","family":"Pauling","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, Somerset, UK"},{"name":"School of Pharmacy and Pharmacology, University of Bath, Bath, Somerset, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Spencer","sequence":"additional","affiliation":[{"name":"Liverpool Interstitial Lung Disease Service, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa I","family":"Adamali","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Gunawardena","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2025083109573235000_8.1.e000829.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2025083109573235000_8.1.e000829.2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"2025083109573235000_8.1.e000829.3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000555"},{"key":"2025083109573235000_8.1.e000829.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800"},{"key":"2025083109573235000_8.1.e000829.5","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"2025083109573235000_8.1.e000829.6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"2025083109573235000_8.1.e000829.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083109573235000_8.1.e000829.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025083109573235000_8.1.e000829.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2025083109573235000_8.1.e000829.10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-Term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025083109573235000_8.1.e000829.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150966"},{"key":"2025083109573235000_8.1.e000829.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181141"},{"key":"2025083109573235000_8.1.e000829.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006"},{"key":"2025083109573235000_8.1.e000829.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442"},{"key":"2025083109573235000_8.1.e000829.15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-016-8528-9","article-title":"Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS Collaborative group","volume":"52","author":"Cavagna","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025083109573235000_8.1.e000829.16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaneurol.2017.3872","article-title":"New criteria needed for antisynthetase syndrome","volume":"75","author":"Casta\u00f1eda","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025083109573235000_8.1.e000829.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212368"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2020-000829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:57:46Z","timestamp":1756659466000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2020-000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,8]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/bmjresp-2020-000829"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2020-000829","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}